The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer
Open accessAbstract
Background and Aims Although the majority of patients with non-alcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizeable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24–52 weeks, which makes testing for drug response costly and time consuming. Methods We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low weekly dose of intraperitoneal carbon tetrachloride (CCl 4 ), which serves as an accelerator. Results C57BL/6J mice were fed a normal chow diet ± CCl 4 or WD ± CCl 4 for 12 and 24 weeks. Addition of CCl 4 exacerbated histological features of NASH, fibrosis, and tumor development induced by WD, which resulted in stage 3 fibrosis at 12 weeks and HCC development at 24 weeks. Furthermore, whole liver transcriptomic analysis indicated that dysregulated molecular pathways in WD/CCl 4 mice and immunologic features were similar to those of human NASH. Conclusions Our mouse NASH model exhibits rapid progression of advanced fibrosis and HCC, and mimics histological, immunological and transcriptomic features of human NASH, suggesting that it will be a useful experimental tool for preclinical drug testing. Lay summary A carefully characterized model has been developed in mice that recapitulates the progressive stages of human fatty liver disease, from simple steatosis, to inflammation, fibrosis and cancer. The functional pathways of gene expression and immune abnormalities in this model closely resemble human disease. The ease and reproducibility of this model make it ideal to study disease pathogenesis and test new treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the FAT-MASH model was used, as this model reproducibly recapitulates the stages of progression of human MASH that include advanced fibrosis and tumors along with changes in the gut microbiome.14,33,34”
From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“These functions normally contribute to tissue repair under homeostatic conditions, but sustained activation in chronic liver diseases drives fibrosis, especially in MASH (41) where they are detectable by expression of desmin and alpha smooth muscle actin (αSMA) using immunofluorescence, and by conservation of gene expression based on single-cell RNA-seq (42-46).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [45]
In the citing paper
“Our laboratory uses a simple rodent model of MASH, the “FAT-MASH” mouse, which robustly develops Fibrosis and Tumors, features of advanced disease, after 24 weeks of a Western diet combined with a small weekly dose of the liver toxin CCl4 (45).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
A scaling normalization method for differential expression analysis of RNA-seq data
Robinson, M. D., & Oshlack, A. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r25 · Cited by 7,876
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationMaeda, S., Kamata, H., Luo, J., Leffert, H. L., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,160
Cited by
Sorted by citations
Items 201–300 of 587
Zhang, J., Yang, Y., Wang, Z., Zhang, X., Zhang, Y., Lin, J., Du, Y., Wang, S., Si, D., Bao, J., et al. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00009 · Cited by 19
Jia, W.-Q., Zhou, T.-C., Dai, J., Liu, Z., Zhang, Y.-F., Zang, D., & Lv, X. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173667 · Cited by 20
Su, M., Cao, D., Wang, Z., Duan, Y., & Huang, Y. P. (2021) · Biomedicines · doi:10.3390/biomedicines10010005 · Cited by 19
Wu, J., Chen, P., Ju, L., Gao, R., Li, S., Huang, Z., Cheng, Y., Gui, S., Qiu, Z., Cheng, J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113132 · Cited by 19
RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression
Wang, Y., Tai, Y., Way, G. W., Zeng, J., Zhao, D., Su, L., Jiang, X., Jackson, K. G., Wang, X., Gurley, E. C., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00910-7 · Cited by 19
Tada, Y., Kasai, K., Makiuchi, N., Igarashi, N., Kani, K., Takano, S., Honda, H., Yanagibashi, T., Watanabe, Y., Usui‐Kawanishi, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113251 · Cited by 19
Mondal, S. A., Sathiaseelan, R., Mann, S. N., Kamal, M., Luo, W., Saccon, T. D., Isola, J. V. V., Peelor, F. F., Li, T., Freeman, W. M., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00256.2022 · Cited by 20
Higgins, C. B., Adams, J. A., Ward, M. H., Greenberg, Z. J., Milewska, M., Sun, J., Zhang, Y., Paracatu, L. C., Dong, Q., Ballentine, S. J., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102835 · Cited by 19
Babiy, B., Ramos‐Molina, B., Ocaña, L., Sacristán, S., Burgos‐Santamaría, D., Martı́nez-Botas, J., Busto, R., Busto, R., Frutos, M. D., Albillos, A., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159318 · Cited by 25
Dang, J., Cai, T., Tuo, Y., Peng, S., Wang, J., Gu, A., Li, J., Ding, L., Du, S., & Wang, L. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c04232 · Cited by 20
Rao, A., van de Peppel, I. P., Gumber, S., Karpen, S. J., & Dawson, P. A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00060 · Cited by 18
Xie, Y., Huang, Y., Li, Z.-Y., Jiang, W., Shi, N.-X., Lu, Y., Cao, G., Yin, Z., & Lin, X.-J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02001-2 · Cited by 18
Cai, H., Bai, Z., & Ge, R.-L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.01.002 · Cited by 19
Bhattacharya, D., Becker, C., Readhead, B. P., Goossens, N., Buros, J. L., Fiel, M. I., Cousens, L. P., Magnusson, B., Backmark, A., Hicks, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99008-2 · Cited by 20
Self-citationMuto, H., Ito, T., Tanaka, T., Yokoyama, S., Yamamoto, K., Imai, N., Ishizu, Y., Maeda, K., Honda, T., Ishikawa, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98254-8 · Cited by 18
Zhang, Y., Yang, X., Bi, T., Wu, X., Wang, L., Ren, Y., Ou, Y., Xie, C., Li, K., Ran, H., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108639 · Cited by 18
A multi-omic landscape of steatosis-to-NASH progression
Xiang, L., Li, X., Luo, Y., Zhou, B., Liu, Y., Li, Y., Wu, D., Jia, L., Zhu, P., Zheng, M., et al. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac034 · Cited by 18
Huang, H., Wei, S., Wu, X., Zhang, M., Zhou, B., Huang, D., & Dong, W. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116438 · Cited by 18
Comparison of Animal Models for the Study of Nonalcoholic Fatty Liver Disease
Zheng, Q. R., Zhu, M., Zeng, X., Liu, W., Fu, F., Li, X., Liao, G., Lu, Y., & Chen, Y. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100129 · Cited by 20
Lin, S., Wu, W., Cheng, Y., Zhang, J., Jiang, D., Ren, T., Ding, W.-J., Liu, M., Chen, Y., & Fan, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01027-8 · Cited by 18
Al‐Rashood, S. T., Al-Asmari, A. K., Alotaibi, A. K., Manthiri, R. A., Rafatullah, S., Hasanato, R. M. W., Khan, H. A., Ibrahim, K. E., & Wali, A. F. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.05.010 · Cited by 18
MiR-29a Curbs Hepatocellular Carcinoma Incidence via Targeting of HIF-1α and ANGPT2
Huang, Y.-H., Lian, W.-S., Wang, F.-S., Wang, P., Lin, H.-Y., Tsai, M.-C., & Yang, Y.-L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031636 · Cited by 16
An overview of mouse models of hepatocellular carcinoma
Zheng, H., Xue, H., & Yun, W.-J. (2023) · Infectious Agents and Cancer · doi:10.1186/s13027-023-00524-9 · Cited by 19
ACBP/DBI neutralization for the experimental treatment of fatty liver disease
Motiño, O., Lambertucci, F., Joseph, A., Durand, S., Anagnostopoulos, G., Li, S., Carbonnier, V., Nogueira-Recalde, U., Montégut, L., Chen, H., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01410-6 · Cited by 17
Experimental Models for Preclinical Research in Hepatocellular Carcinoma
Molina-Sánchez, P., & Lujambio, A. (2019) · Molecular and translational medicine · doi:10.1007/978-3-030-21540-8_16 · Cited by 18
Kang, L., Ma, X., Yu, F., Xu, L., & Li, L. (2024) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2406.06048 · Cited by 16
Liver regeneration biology: Implications for liver tumour therapies
Hadjittofi, C., Feretis, M., Martin, J. L., Harper, S., & Huguet, E. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i12.1101 · Cited by 18
Li, T., Chen, Y., Tan, P., Shi, H., Huang, Z., Cai, T., Cheng, Y., Du, Y., & Fu, W. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105737 · Cited by 16
Metabolic benefits of 17α-estradiol in liver are partially mediated by ERβ in male mice
Mondal, S. A., Mann, S. N., van der Linden, C., Sathiaseelan, R., Kamal, M., Das, S., Bubak, M. P., Logan, S., Miller, B. F., & Stout, M. B. (2023) · Scientific Reports · doi:10.1038/s41598-023-37007-1 · Cited by 17
Fujiwara, N., & Nakagawa, H. (2023) · Cancer Science · doi:10.1111/cas.15925 · Cited by 14
Self-citationSharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Challenges and opportunities in drug development for nonalcoholic steatohepatitis
Ocker, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172913 · Cited by 17
Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview
Torres, S., Abdullah, Z., Brol, M. J., Hellerbrand, C., Fernández, M., Fiorotto, R., Klein, S., Königshofer, P., Liedtke, C., Lotersztajn, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062027 · Cited by 17
Diniz, A. B., Antunes, M. M., Lacerda, V. A. D. S., Nakagaki, B. N., Lopes, M. A. F., Oliveira, H. M. D. C., Mattos, M. S., Mafra, K., de Miranda, C. D. M., Costa, K. M. D. O., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100117 · Cited by 16
Barahona, I., Rada, P., Calero‐Pérez, S., Grillo-Risco, R., Pereira, L., Soler‐Vázquez, M. C., Laiglesia, L. M., Moreno-Aliaga, M. J., Herrero, L., Serra, D., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01023-x · Cited by 16
Mouse Models of Hepatocellular Carcinoma
Carlessi, R., Köhn‐Gaone, J., Olynyk, J. K., & Tirnitz‐Parker, J. E. E. (2019) · Codon Publications eBooks · doi:10.15586/hepatocellularcarcinoma.2019.ch4 · Cited by 17
Toll-like receptor 2 signaling in liver pathophysiology
Getachew, A., Hussain, M., Huang, X., & Li, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119941 · Cited by 15
Wang, Y., Yang, Y., Zhao, Z., Sun, H., Luo, D., Huttad, L., Zhang, B., & Han, B. (2022) · BMC Cancer · doi:10.1186/s12885-022-09465-9 · Cited by 15
Zheng, M., Ai, Z., Guo, Y., Chen, Y., Xie, P., & An, W. (2022) · Oncogene · doi:10.1038/s41388-022-02549-7 · Cited by 15
Zhou, R., Song, Y., Xu, C., Zhang, Y., Wu, X., Zhang, L., Luo, X., Zhao, H. Q., Liu, M., Xu, J., et al. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18440 · Cited by 15
Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression
Akl, M. G., Li, L., & Widenmaier, S. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158046 · Cited by 16
A guide to pathophysiology, signaling pathways, and preclinical models of liver fibrosis
Sultana, M., Islam, M. A., Khairnar, R., & Kumar, S. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112448 · Cited by 15
Zhao, R., Xiang, B., Dolinsky, V. W., Xia, M., & Shen, G. X. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108778 · Cited by 19
Zhou, Z., Ren, Q., Jiao, S., Cai, Z., Geng, X., Deng, L., Wang, B., Hu, L., Zhang, L., Yang, Y., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114061 · Cited by 15
Lan, T., Xu, T., Fu, Y., Jiang, S., Liang, X., Yu, Z., Pan, L., Rong, X., & Guo, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.864703 · Cited by 15
Vargas-Pozada, E. E., Ramos‐Tovar, E., Rodríguez-Callejas, J. D., Cardoso-Lezama, I., Galindo‐Gómez, S., Gil-Becerril, K. M., Vásquez-Garzón, V. R., Arellanes‐Robledo, J., Tsutsumi, V., Villa‐Treviño, S., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100780 · Cited by 15
Minocha, S., Villeneuve, D., Praz, V., Moret, C., Lopes, M., Pinatel, D., Rib, L., Guex, N., & Herr, W. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00405-18 · Cited by 15
Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels
Xu, D., Zhang, Z., Zhu, Z., Wei, W., Bai, Y., Wang, W., Zhu, Y., Alimujiang, A., Shi, Y., Zhang, Z., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.07.013 · Cited by 15
Zhang, B., Lapenta, K., Wang, Q., Nam, J. H., Chung, D., Robert, M. E., Nathanson, M. H., & Yang, X. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100887 · Cited by 13
Romualdo, G. R., Heidor, R., Bacil, G. P., Moreno, F. S., & Barbisan, L. F. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121994 · Cited by 14
Liu, L., Deng, L., Wei, W., Li, C., Lu, Y., Bai, J., Li, L., Zhang, H., Jin, N., Li, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813997 · Cited by 15
Hsieh, M.-H., Wei, Y.-L., Li, L., Nguyen, L. H., Lin, Y.-H., Yong, J. M., Sun, X.-X., Wang, X., Luo, X.-Y., Knutson, S. K., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci165734 · Cited by 12
Li, Z., Xu, Y., Cai, Z., Wang, X., Ren, Q., Zhou, Z., & Xie, R. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103803 · Cited by 14
Huang, H., Zhou, X., Liu, Y., Fan, S., Liao, L., Huang, J. L., Shi, C., Yu, L., Pen, J.-J., Luo, C., et al. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11944 · Cited by 13
Inhibition of eIF6 Activity Reduces Hepatocellular Carcinoma Growth: An In Vivo and In Vitro Study
Scagliola, A., Miluzio, A., Mori, G., Ricciardi, S., Oliveto, S., Manfrini, N., & Biffo, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147720 · Cited by 14
Unraveling the Potential Role of Tecomella undulata in Experimental NASH
Srinivas, A. N., Suresh, D., Suvarna, D., Pankaj, P., Giri, S. R., Suman, Satish, S., Chidambaram, S. B., & Kumar, D. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043244 · Cited by 14
Advances in experimental animal models of hepatocellular carcinoma
Li, J., Wang, X., Ren, M., He, S., & Zhao, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6163 · Cited by 14
Yashaswini, C. N., Cogliati, B., Qin, T., To, T., Williamson, T., Papp, T. E., Li, K., Rasul, R., Chen, L., Lightstone, A., et al. (2025) · doi:10.1101/2025.02.25.640143 · Cited by 13
Self-citationSt. Rose, K., Yan, J., Xu, F., Williams, J., Dweck, V., Saxena, D., Schwabe, R. F., & Caviglia, J. M. (2022) · Hepatology Communications · doi:10.1002/hep4.2035 · Cited by 14
Chen, W., Wang, P., Xie, Y. H., Xie, D., Wang, H., Bu, N., Lin, J., Wu, M., Xia, H., Cheng, C., et al. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111507 · Cited by 13
Li, Y., Zhang, L., Jiao, J., Ding, Q., Li, Y., Zhao, Z., Luo, J., Chen, Y., Ruan, X. Z., & Zhao, L. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166800 · Cited by 16
Srinivas, A. N., Suresh, D., Chidambaram, S. B., Santhekadur, P. K., & Kumar, D. P. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31151 · Cited by 12
Ji, Y. R., Duan, Y., Li, Y., Lu, Q., Liu, D., Yang, Y., Chang, R., Jing, T., Yao, W., Yin, J., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16378 · Cited by 14
Bissoondial, T. L., Han, Y., Mullan, S., Pabla, A. K., Spahn, K., Shi, S., Zheng, L., Zhou, P., Jiang, K., Prakash, N., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10100784 · Cited by 13
Huang, Y.-L., Gregorio, C. D., Silva, V., Elorza, Á. A., Léniz, P., Aliaga-Tobar, V., Maracaja‐Coutinho, V., Budini, M., Ezquer, F. E., & Ezquer, M. (2023) · Cells · doi:10.3390/cells12040636 · Cited by 15
Nagy, D., Maude, H., Birdsey, G. M., RANDI, A. M., & Cebola, I. (2023) · Journal of Molecular Endocrinology · doi:10.1530/jme-23-0026 · Cited by 12
Han, L., Bittner, S., Dong, D., Cortez, Y., Dulay, H., Arshad, S., Shen, W., Kraemer, F. B., & Azhar, S. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110538 · Cited by 13
Mouse models of nonalcoholic steatohepatitis and their application to new drug development
Phung, H. H., & Lee, C. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01410-5 · Cited by 13
Antunes, M. M., Diniz, A. B., Oliveira, H. M. D. C., Mendes, G. A. M., Freitas‐Lopes, M. A., Costa, K. M. D. O., Mafra, K., Nakagaki, B. N., Mattos, M. S., de Miranda, C. D. M., et al. (2020) · Nutrition · doi:10.1016/j.nut.2020.110938 · Cited by 12
Wang, X., Jin, R., Li, X., Yang, Q., Teng, X., Liu, F., Wu, N., Rao, H., & Liu, F. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1172058 · Cited by 12
Tan, P. K., Ostertag, T. M., Rosenthal, S. B., Chilin-Fuentes, D., Aidnik, H., Linker, S. B., Murphy, K., Miner, J. N., & Brenner, D. A. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.12.005 · Cited by 12
Wang, Y., Liu, C., Yang, Y., Zhang, L. R., Guo, X., Niu, C., Zhang, N., Ding, J., & Wu, J. H. (2024) · The FASEB Journal · doi:10.1096/fj.202400573rr · Cited by 12
Xu, Z.-X., Tang, C., Song, X., Liu, Z.-N., Zhou, J., Shi, Q., Yu, C.-H., & Xu, C. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110249 · Cited by 14
Multiple Applications of Different Exercise Modalities with Rodents
Börzsei, D., Szabó, R., Hoffmann, A., Harmath, A., Sebestyén, J., Osman, J., Juhász, B., Priksz, D., Varga, C., & Pósa, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3898710 · Cited by 13
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Zang, Y., Shi, J., Zhao, G., Tang, B., Liu, M., Yao, B., Wang, G., Pan, H., Yang, S., Deng, R., et al. (2026) · Nature · doi:10.1038/s41586-026-10633-1 · Cited by 11
Zhang, L., Jing-bo, F., Zhang, X.-W., Liu, Y., Shi, W., Hidayat, K., Xu, J., Yuan, L., & Qin, L. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105596 · Cited by 11
Chen, Y., Yu, M., Chen, L., Mao, J., Wang, W., Yang, Z., Cao, Z., Liu, Y., Wei, M., Zhang, L., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116358 · Cited by 11
Araujo, L. C. C., Dias, C. C., SUCUPIRA, F., Ramalho, L. N. Z., & Camporez, J. P. (2024) · Bioscience Reports · doi:10.1042/bsr20231532 · Cited by 11
Qu, H., Zhang, D., Liu, J., Deng, J., Xie, R., Zhang, K., Li, H., Tao, P., Wang, G., Sun, J. L., et al. (2024) · Engineering · doi:10.1016/j.eng.2024.05.005 · Cited by 10
Cai, C., Luo, H., Jin, P., Zhen, X., Shen, X., Xi, X., Zhu, J., Fang, Y., Chen, X., Wang, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.046 · Cited by 11
Dimeric Histidine as a Novel Free Radical Scavenger Alleviates Non-Alcoholic Liver Injury
Zhao, Z., Fu, C., Zhang, Y., & Fu, A. (2021) · Antioxidants · doi:10.3390/antiox10101529 · Cited by 12
Estimating Drug Efficacy with a Diet-Induced NASH Model in Chimeric Mice with Humanized Livers
Kisoh, K., Sugahara, G., Ogawa, Y., Furukawa, S., Ishida, Y., Okanoue, T., Kohara, M., & Tateno, C. (2021) · Biomedicines · doi:10.3390/biomedicines9111647 · Cited by 11
Huang, S., Deng, Z., Wang, W., Liao, G., Zhao, Y., Zhong, H., Zhang, Q., Liu, J., Mao, X., Chen, B., et al. (2023) · International Journal of Endocrinology · doi:10.1155/2023/4950597 · Cited by 11
Stauffer, W. T., Goodman, A. Z., Bobardt, M. D., Ure, D., Foster, R. T., & Gallay, P. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298211 · Cited by 11
Jun, H., Liu, S., Knights, A. J., Zhu, K., Ma, Y., Gong, J., Lenhart, A. E., Peng, X., Huang, Y., Ginder, J. P., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002728 · Cited by 11
Wang, X., Lu, L.-J., Li, Y., & Xu, C. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120925 · Cited by 12
Li, S., Chen, F., Zou, Y., Ning, L., Zhang, G., Zhang, S., & Yao, Q. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-4809 · Cited by 10
Bi, H., Zhou, B., Yang, J., Lü, Y., Mao, F., & Song, Y. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121951 · Cited by 10
Reis-Costa, A., Belew, G. D., Viegas, I., Tavares, L. C., Meneses, M. J., Patrício, B. G., Gastaldelli, A., Macedo, M. P., & Jones, J. G. (2024) · Nutrients · doi:10.3390/nu16142186 · Cited by 13
Ogiso, H., Miura, K., Nagai, R., Osaka, H., & Aizawa, K. (2024) · Antioxidants · doi:10.3390/antiox13111293 · Cited by 10
Ma, Z.-J., Qiu, Y., Yu, Z.-W., Song, T., Hu, Y., Peng, A., & Qi, R. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.016 · Cited by 10
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases
Durazzo, M., Ferro, A., Navarro‐Tableros, V., Gaido, A., Fornengo, P., Altruda, F., Romagnoli, R., Moestrup, S. K., Calvo, P. L., & Fagoonee, S. (2025) · Biomolecules · doi:10.3390/biom15010121 · Cited by 11
Si, Z., Zhao, S., Zhang, Z., Chen, T., Wang, R., Dong, C., Wang, K., Sun, C., Song, Z., Shen, Z., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04353-y · Cited by 10
Chen, L., Liang, Z., Mao, J., Liao, Z., Liu, Y., Ou, D., Liu, C., & Li, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00119 · Cited by 10
Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation
Algueró-Nadal, A., Mol, H., Zoppolato, E., Kowalczyk, W., Sansores-García, L., Soheily, S., Hillen, H., Huffel, L. V., Haele, M. V., Corral-Ibáñez, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.002 · Cited by 10
Lequoy, M., Gigante, E., Couty, J., & Desbois‐Mouthon, C. (2020) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2019-0044 · Cited by 12
de Freitas, L. B. R., Longo, L., Filippi‐Chiela, E. C., de Souza, V. E. G., Behrens, L. M. P., Pereira, M. H. M., Leonhard, L. C., Zanettini, G., Pinzon, C. E., Luchese, E., et al. (2022) · Biomolecules · doi:10.3390/biom12121773 · Cited by 10
Bacil, G. P., Romualdo, G. R., Piagge, P. M. F. D., Cardoso, D. R., Vinken, M., Cogliati, B., & Barbisan, L. F. (2023) · Antioxidants · doi:10.3390/antiox12020290 · Cited by 10
Yang, H. Y., Chen, J., & Li, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1243220 · Cited by 10
Tsutsui, Y., Mori, T., Yoshio, S., Sato, M., Sakata, T., Yoshida, Y., Kawai, H., Yoshikawa, S., Yamazoe, T., Matsuda, M., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000236 · Cited by 10
Metadata
- Authors
- Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., & Friedman, S. L.
- Affiliations
- Tanabe Pharma Corporation (Japan) (JP)
- Icahn School of Medicine at Mount Sinai (US)
- Mount Sinai Hospital (US)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 69
- Issue
- 2
- Pages
- 385-395
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC6054570
- OpenAlex
- W2790198401
- Cited by
- 583
- References
- 56
- Citations by year
- 2026: 65 · 2025: 86 · 2024: 90 · 2023: 91 · 2022: 93 · 2021: 62 · 2020: 52 · 2019: 34 · 2018: 10
- FWCI
- 30.84
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-10-01)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Hepatology (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- NIH
- NIDDK (DK099558)
- European Commission (ERC-2014-AdG-671231)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, mouse model, Western diet, carbon tetrachloride, liver fibrosis, hepatocellular carcinoma, liver transcriptome, immune abnormalities, preclinical drug testing
- MeSH terms
- Animals, Carbon Tetrachloride, Disease Models, Animal, Fatty Liver, Inflammation, Liver Cirrhosis, Liver Neoplasms, Mice, Inbred C57BL, Reproducibility of Results, Disease Progression, Gene Expression Profiling, Mice, Diet, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
